## Supplementary materials

Training






Validation






Figure 1. The full range of the Box Plots.

Table S1

Table 1A: Training cohort

| Lung cancer subtypes |  |  |  |  |  | Age (yr) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Adenocarcinoma (n) | Squamous (n) | Non Squamous (n) | Small cell (n) | Metastasis (n) | Mean $\pm$ SD |
| Female ( $\mathrm{n}=18$ ) | 13 | 5 | - | - | - | $47 \pm 2$ |
| Male ( $\mathrm{n}=13$ ) | 9 | 3 | - | 1 | - | $56 \pm 2$ |
| Total ( $\mathrm{n}=31$ ) | 22 | 8 | - | 1 | - | $52 \pm 2$ |

** Majority of patient at advanced stage 3+
Table 1B: Validation cohort
Table 1B: Validation cohort

|  | Lung cancer subtypes | Age (yr) |  |  |  |  |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- |
|  | Adenocarcinoma (n) | Squamous (n) | Non Squamous (n) | Small cell (n) | Metastasis (n) | Mean $\pm$ SD |
| Female $(\mathrm{n}=9)$ | 2 | 1 | 2 | 2 | $54 \pm 3$ |  |
| Male $(\mathrm{n}=17)$ | 2 | 5 | 3 | - | $56 \pm 3$ |  |
| Total $(\mathrm{n}=26)$ | 5 | 6 | 5 | 2 | $56 \pm 2$ |  |

** Majority of patient at advanced stage 3+

Table 1C: Summary table of normal vs Lung cancer

|  | Tranining |  |  | Validation |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Lung Cancer ( n ) | Normal ( n ) | Pvalue | Lung Cancer ( n ) | Normal ( n ) | Pvalue |
| Samples | 31 | 15 |  | 26 | 15 |  |
| Age: | Mean $\pm$ SD | Mean $\pm$ SD |  | Mean $\pm$ SD | Mean $\pm$ SD |  |
| Mean (Range) (yr) | 50.7(27-75) | 43.7 (27-56) | 0.06 | 55.7 (27-70) | 43.7 (27-56) | 0.000213 |
| Sex: |  |  |  |  |  |  |
| Male | 13 | 6 | 0.75 | 17 | 6 | 0.12 |
| Female | 18 | 9 |  | 9 | 9 |  |

Table S2

| Targeted metabolites | Mcubolics Classifraion | Palien Clasiication | Cotorn | Nunberof samples | Number or missing samples | min valic of reclublice | max value of mexubolic | Mdian | Mean |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Valine | Amino Acids and Biogenic Amines | Normal | Training | 15 | 0 | 198 | 376 | 263 | 267.0667 |
| Patrescine | Polyaminc Metabolites | Nomal | Training | 15 | 0 | 0.104 | 0.269 | 0.154 | 0.1637 |
| Mchioninc | Polyamine Melabolites | Nomal | Truining | 15 | 0 | 17.7 | 35.9 | 25.8 | 26.5133 |
| Arginine | Polyaminc Mctabolites | Nomal | Training | 15 | 0 | 72.4 | 234 | 120 | 1377933 |
| Omilhinc | Polyamine Melabolites | Nomal | Traing | 15 | 0 | 56.6 | 142 | 72.5 | 79.14 |
| Spemidine | Polyaminc Mctabolites | Normal | Training | 15 | 0 | 0.256 | 13.1 | 0.335 | 2.7091 |
| C10. 2 | Acylcarailios | Nomal | Training | 15 | 0 | 0.0297 | 0.076 | 0.1493 | 0.1489 |
| C18. 2 | Acylcarnitines | Normal | Training | 15 | 0 | 0.0238 | 0.0853 | 0.0567 | 0.0522 |
|  | Glyccrophospholipids | Nomal | Training | 15 | 0 | 12.1476 | 29.259 | 20.1631 | 19.521 |
| PC.as.C32.2 | Glycerophospholipids | Nomal | Traing | 15 | 0 | 1.5099 | 4.5478 | 3.0779 | 2.9107 |
| PC a a C36.0 | Glycrerophospholipids | Normal | Training | 15 | 0 | 1.008 | 3.1557 | 1.7134 | 1.803 |
| PC.ac. C33.0 | Glycerophospholipids | Nomal | Training | 15 | 0 | 0.4003 | 1.157 | 0.6427 | 0.6749 |
| Valine | Amino Acids and Biogncic Amines | Lung Cancer | Training | 31 | 0 | 135 | 369 | 193 | 208 |
| Putressinc | Polyamine Metabolites | L.ung Cancer | Training | 31 | 0 | 0.115 | 1.13 | 0.2475 | 0.3099 |
| Mectioninc | Polyamine Metabolites | Lung Cancor | Training | 31 | 0 | 11.6 | 63.6 | 22.25 | 24.0633 |
| Argininc | Polyamine Metabolites | L.ung Cancer | Training | 31 | 0 | 37.7 | 262 | 95.6 | 112.2867 |
| Omithine | Polyamine Metabolites | Lung Cancor | Trining | 31 | 0 | 47.1 | 167 | 69.35 | 76.13 |
| Spemidinc | Polyaminc Metabolites | Lumg Cancer | Training | 31 | 0 | 0.333 | 9.9 | 0.335 | 2.14 |
| $\mathrm{ClO}_{10} 2$ | Acylearaitios | L.ung Cancor | Training | 31 | 0 | 0.0255 | 0.0889 | 0.1376 | 0.139 |
| C18.2 | Acylcarnitities | Lugg Cancer | Training | 31 | , | 0.0208 | 0.1127 | 0.0398 | 0.0438 |
| lysoPC.aC18. 2 | Glycerophospholipids | L.umg Cancer | Training | 31 | 0 | 3.815 | 28.7725 | 14.1162 | 13.3528 |
| PC.aac 32.2 | Glycerophospholipids | Lung Cancor | Training | 31 | 0 | 0.2588 | 4.3734 | 1.4442 | 1.78149 |
| PC.aa. C 36.0 | Glycerophospholipids | Lumg Cancer | Training | 31 | 0 | 0.3143 | 3.6154 | 1.8023 | 2.0029 |
| PCat.C36.0 | Glycerophospholipids | Lung Cancer | Training | 31 |  | 0.4613 | 1.5473 | 0.8711 | 0.9148 |
| Valine | Amino Acids and Biogenic Amints | Normal | Validation | 15 | 0 | 233 | 442 | 280 | 294.5333 |
| Argininc | Polyamine Metabolites | Nomal | Validataion | 15 | 0 | 75.1 | 237 | 116 | 139.88 |
| Oruithine | Polyamine Metabolites | Nomal | Validation | 15 | 0 | 27 | 90 | 47.3 | 50.7533 |
| Methionine | Polyaminc Metabolites | Nomal | Validation | 15 |  | 27.5 | 63.1 | 38.4 | 39.92 |
| Sxemididinc | Polyamine Metabolites | Nomal | Validation | 15 | 0 | 0.164 | 0.319 | 0.208 | 0.2118 |
| Spemine | Polyaminc Metabolites | Nomal | Validation | 15 | 0 | 0.23 | 0.332 | 0.263 | 0.2655 |
| Diacecylyp | Acylcarnitiocs | Nomal | Validation | 15 | 0 | 0.0287 | 0.0473 | 0.0364 | 0.0369 |
| Decadienylcamitine (C10.2) | Acylcarnitines | Nomal | Validation | 13 | 2 | 0.02 | 0.29 | 0.07 | 0.1008 |
| PC.aa. 32.2 | Glycerophospholipids | Nomal | Validation | 15 | 0 | 2.37 | 11.89 | 7.69 | 7.3293 |
| PC.ae. C36.0 | Glycrerophospholipids | Normal | Validation | 15 | 0 | 1.17 | 286 | 1.85 | 1.9033 |
|  | Glycerophosphallipids | Nomal | Validation | 15 | 0 | 3.93 | 7.59 | 4.87 | 5.4073 |
| MTA | Polyamine Melabolites | Lung Cancer | Validation | 9 | 17 | 0.0041 | 0.267 | 0.0945 | 0.1067 |
| Valine | Amino Acids and Biogcnic Amines | Lums Cancer | Validation | 26 | 0 | 120 | 316 | 192 | 204.6154 |
| Argininc | Polyamine Melabolites | L.ang Cancer | Validataion | 26 | 0 | 51.6 | 252 | 89.8 | 116.3347 |
| Omithine | Polyaminc Mctabolitrs | Lume Cancer | Validation | 26 | , | 174 | 93.7 | 47.15 | 459423 |
| Mchtioninc | Polyamine Metabolites | 1.ung Cancer | Validation | 26 | 0 | 14.5 | 50.8 | 31.8 | 31.4423 |
| Putrescine | Polyaminc Metabolites | Lung Cancer | Validation | 3 | 23 | 0.0219 | 0.182 | 0.112 | 0.1053 |
| Sprmidinc | Polyamine Metabolites | L.ung Cancer | Validation | 26 | 0 | 0.154 | 0.464 | 0.2285 | 0.2331 |
| Spermine | Polyamine Metabolites | Lung Cancor | Validation | 26 | 0 | 0.245 | 0.482 | 0.2885 | 0.3108 |
| Diacectyspemine | Acylcaraitites | Lumg Cancer | Validation | 26 | , | 0.0297 | 0.358 | 0.0423 | 0.9611 |
| Deceadienylcamiline ( $\mathbf{C} 10.2$ ) | Acylcarailios | 1.ang Cancer | Validation | 15 | 11 | 0.01 | 0.21 | 0.38 | 0.2813 |
| PC.aaC32.2 | Glycropopospholipids | Lung Cancer | Validation | 26 | 0 | 3.08 | 38.67 | 9.48 | 12.1392 |
| PC.as.C36.0 | Glycerophospholipids | L.ung Cancer | Validation | 26 |  | 1.14 | 3.86 | 2.095 | 2.1485 |
| $1 \mathrm{ysoPCaCl8}$. | Glycerophospholipids | Lung Cancor | Validation | 26 | 0 | 0.6 | 9.44 | 3.13 | 3.5692 |

Table S3

Table 3A: Univariate Summary Measure of each Metabolite

|  | Training |  |  | Validation |  |  |
| :--- | :---: | :---: | :---: | :---: | :---: | :---: |
|  | AUC | P value | FC | AUC | P value | FC |
| Arginine | $6.61 \mathrm{E}-01$ | $1.30 \mathrm{E}-01$ | $-3.25 \mathrm{E}-01$ | $6.64 \mathrm{E}-01$ | $1.33 \mathrm{E}-01$ | $-3.26 \mathrm{E}-01$ |
| C10.2 | $7.71 \mathrm{E}-01$ | $9.44 \mathrm{E}-03$ | $-1.28 \mathrm{E}-01$ | NA | NA | NA |
| C18.2 | $6.73 \mathrm{E}-01$ | $1.85 \mathrm{E}-01$ | $-1.11 \mathrm{E}-01$ | NA | NA | NA |
| Diacetylspermi | NA | NA | NA | $7.60 \mathrm{E}-01$ | $2.59 \mathrm{E}-02$ | $2.12 \mathrm{E}-01$ |
| lysoPC.a.C18. | $7.73 \mathrm{E}-01$ | $1.86 \mathrm{E}-03$ | $-6.60 \mathrm{E}-01$ | $7.65 \mathrm{E}-01$ | $3.16 \mathrm{E}-03$ | $-8.15 \mathrm{E}-01$ |
| Methionine | $6.67 \mathrm{E}-01$ | $4.01 \mathrm{E}-01$ | $-2.19 \mathrm{E}-01$ | $6.85 \mathrm{E}-01$ | $2.08 \mathrm{E}-02$ | $-3.44 \mathrm{E}-01$ |
| Ornithine | $5.46 \mathrm{E}-01$ | $6.97 \mathrm{E}-01$ | $-6.91 \mathrm{E}-02$ | $5.69 \mathrm{E}-01$ | $3.21 \mathrm{E}-01$ | $-1.70 \mathrm{E}-01$ |
| PC.aa.C32.2 | $7.96 \mathrm{E}-01$ | $2.12 \mathrm{E}-03$ | $-9.63 \mathrm{E}-01$ | $6.94 \mathrm{E}-01$ | $2.75 \mathrm{E}-02$ | $5.91 \mathrm{E}-01$ |
| PC.aa.C36.0 | $5.71 \mathrm{E}-01$ | $4.13 \mathrm{E}-01$ | $7.44 \mathrm{E}-02$ | NA | NA | NA |
| PC.ac.C36.0 | $7.51 \mathrm{E}-01$ | $6.69 \mathrm{E}-03$ | $4.28 \mathrm{E}-01$ | $6.12 \mathrm{E}-01$ | $2.53 \mathrm{E}-01$ | $1.64 \mathrm{E}-01$ |
| Putrescine | $8.33 \mathrm{E}-01$ | $2.03 \mathrm{E}-02$ | $6.64 \mathrm{E}-01$ | NA | NA | NA |
| Spermidine | $5.89 \mathrm{E}-01$ | $6.12 \mathrm{E}-01$ | $2.46 \mathrm{E}-01$ | $6.29 \mathrm{E}-01$ | $1.11 \mathrm{E}-01$ | $1.90 \mathrm{E}-01$ |
| Spermine | NA | NA | NA | $7.67 \mathrm{E}-01$ | $5.20 \mathrm{E}-03$ | $1.95 \mathrm{E}-01$ |
| Valine | $8.04 \mathrm{E}-01$ | $2.19 \mathrm{E}-03$ | $-3.83 \mathrm{E}-01$ | $9.09 \mathrm{E}-01$ | $2.58 \mathrm{E}-06$ | $-5.33 \mathrm{E}-01$ |

AUC - Area Under the Curve; FC - Fold Change, NA - Not available

Table 3B: t-tests for key Metabolites using training data (A) and validation data (B)

| Training Data A |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: |
| Metabolites | t-statistic | P value | $-\log 10$ (p) | FDR |
| Putrescine | $3.54 \mathrm{E}+00$ | $9.88 \mathrm{E}-04$ | $3.01 \mathrm{E}+00$ | $6.44 \mathrm{E}-03$ |
| Valine | $-3.51 \mathrm{E}+00$ | $1.07 \mathrm{E}-03$ | $2.97 \mathrm{E}+00$ | $6.44 \mathrm{E}-03$ |
| $\begin{aligned} & \text { lysoPC.a.C18. } \\ & 2 \end{aligned}$ | $3.30 \mathrm{E}+00$ | $1.97 \mathrm{E}-03$ | $2.70 \mathrm{E}+00$ | $7.89 \mathrm{E}-03$ |
| PC.aa.C32.2 | $-3.18 \mathrm{E}+00$ | $2.72 \mathrm{E}-03$ | $2.57 \mathrm{E}+00$ | $8.15 \mathrm{E}-03$ |
| PC.ae.C36.0 | $3.02 \mathrm{E}+00$ | $4.27 \mathrm{E}-03$ | $2.37 \mathrm{E}+00$ | $9.32 \mathrm{E}-03$ |
| C10.2 | $-2.99 \mathrm{E}+00$ | $4.66 \mathrm{E}-03$ | $2.33 \mathrm{E}+00$ | $9.32 \mathrm{E}-03$ |
|  |  |  |  |  |
| Validation Data B |  |  |  |  |
| Metabolites | t-statistic | P value | $-\log 10$ (p) | FDR |
| Valine | $-5.50 \mathrm{E}+00$ | $2.58 \mathrm{E}-06$ | $5.59 \mathrm{E}+00$ | $2.58 \mathrm{E}-05$ |
| $\begin{aligned} & \text { lysoPC.a.C18. } \\ & 2 \end{aligned}$ | $-3.15 \mathrm{E}+00$ | $3.16 \mathrm{E}-03$ | $2.50 \mathrm{E}+00$ | $1.58 \mathrm{E}-02$ |
| Spermine | $2.96 \mathrm{E}+00$ | $5.20 \mathrm{E}-03$ | $2.28 \mathrm{E}+00$ | $1.73 \mathrm{E}-02$ |
| Methionine | $-2.41 \mathrm{E}+00$ | $2.08 \mathrm{E}-02$ | $1.68 \mathrm{E}+00$ | $4.59 \mathrm{E}-02$ |
| Diacetylsperm ine | $2.32 \mathrm{E}+00$ | $2.59 \mathrm{E}-02$ | $1.59 \mathrm{E}+00$ | $4.59 \mathrm{E}-02$ |
| PC aa. C32:2 | $2.29 \mathrm{E}+00$ | $2.75 \mathrm{E}-02$ | $1.56 \mathrm{E}+00$ | $4.59 \mathrm{E}-02$ |

$-\log 10$ (p), FDR False Discovery Rate; $t$-statistic,

Table 3C: Training data, generalized linear regression multivariate model statistics - key metabolites

|  | Estimate | S.E. | P value |
| :---: | :---: | :---: | :---: |
| (Intercept) | 0.9438 | 0.2969 | 0.0029 |
| Valine | 0.0012 | 0.0011 | 0.2724 |
| Putrescinc | -0.6203 | 0.2991 | 0.0447 |
| PC.aa.C32.2 | 0.1294 | 0.0563 | 0.027 |
| PC.aa.C36.0 | -0.2273 | 0.08 | 0.0071 |
| C10.2 | 10.3848 | 5.2603 | 0.0555 |

Table 3D: Validation data, generalized linear regression multivariate model statistics - key metabolites

|  | Estimate | S. E. | P Value |
| :---: | :---: | :---: | :---: |
| (Intercept) | 1.3407 | 0.4139 | 0.0025 |
| Valine | 0.0051 | 0.0009 | $1.84 \mathrm{E}-06$ |
| Spermine | -2.8954 | 1.0274 | 0.0077 |
| Ornithine | -0.007 | 0.0036 | 0.0633 |

S.E., Standard Error

